Loading...
Subclinical diagnosis of cisplatin-induced ototoxicity with biomarkers
Generotti, Charles Cox, Brandon C. Singh, Jarnail Hamilton, Deborah O'Malley, Bert W. Li, Daqing
Generotti, Charles
Cox, Brandon C.
Singh, Jarnail
Hamilton, Deborah
O'Malley, Bert W.
Li, Daqing
Citations
Altmetric:
Genre
Journal article
Date
2022-10-27
Advisor
Committee member
Group
Department
Civil and Environmental Engineering
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.1038/s41598-022-23034-x
Abstract
A mouse model with cisplatin-induced ototoxicity was used in addition to human samples from the ITMAT Biobank at the University of Pennsylvania. Mouse auditory brainstem responses (ABR), inner ear histology, perilymph cisplatin sampling, and measurement of serum prestin via ELISA were performed. Human serum prestin level was measured via ELISA in patients with otological issues after cisplatin treatment and compared to matched controls. Serum prestin was significantly elevated before ABR threshold shifts in mice exposed to cisplatin compared to control mice. Prestin concentration also correlated with the severity of hearing threshold shifts in mice. After an extended rest post-cisplatin treatment, prestin returned to baseline levels in mice and humans. Prestin was significantly elevated in the serum before the onset of objective hearing loss and correlated with the severity of hearing damage indicating that prestin may function as an effective biomarker of cisplatin-induced ototoxicity. Human serum prestin levels responded similarly to mice > 3 weeks from ototoxic exposure with decreased levels of prestin in the serum.
Description
Citation
Generotti, C., Cox, B.C., Singh, J. et al. Subclinical diagnosis of cisplatin-induced ototoxicity with biomarkers. Sci Rep 12, 18032 (2022). https://doi.org/10.1038/s41598-022-23034-x
Citation to related work
Nature Research
Has part
Scientific Reports, Vol. 12
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu